NLRP3 and Insulin resistance: In non-alcoholic fatty liver disease (NAFLD) models, mangiferin (47) mitigated liver injury, insulin resistance, and glucose intolerance by modulating glucolipid metabolism through AMPK activation and NLRP3 inflammasome inhibition [60].